nodes	percent_of_prediction	percent_of_DWPC	metapath
Tazarotene—CYP2C8—Ifosfamide—testicular cancer	0.0884	0.677	CbGbCtD
Tazarotene—Pain of skin—Bleomycin—testicular cancer	0.0575	0.079	CcSEcCtD
Tazarotene—Localized exfoliation—Bleomycin—testicular cancer	0.0503	0.0691	CcSEcCtD
Tazarotene—CYP2C8—Etoposide—testicular cancer	0.0423	0.323	CbGbCtD
Tazarotene—Cheilitis—Dactinomycin—testicular cancer	0.0297	0.0408	CcSEcCtD
Tazarotene—Skin hyperpigmentation—Bleomycin—testicular cancer	0.0228	0.0313	CcSEcCtD
Tazarotene—Skin hyperpigmentation—Ifosfamide—testicular cancer	0.0195	0.0268	CcSEcCtD
Tazarotene—RARB—female gonad—testicular cancer	0.0164	0.116	CbGeAlD
Tazarotene—RARA—gonad—testicular cancer	0.0155	0.11	CbGeAlD
Tazarotene—RXRB—female gonad—testicular cancer	0.0151	0.107	CbGeAlD
Tazarotene—Sensitisation—Epirubicin—testicular cancer	0.0144	0.0197	CcSEcCtD
Tazarotene—RARG—female gonad—testicular cancer	0.0134	0.0949	CbGeAlD
Tazarotene—RXRB—testis—testicular cancer	0.0134	0.0948	CbGeAlD
Tazarotene—Sensitisation—Doxorubicin—testicular cancer	0.0133	0.0183	CcSEcCtD
Tazarotene—Skin exfoliation—Bleomycin—testicular cancer	0.0129	0.0178	CcSEcCtD
Tazarotene—Leukoderma—Methotrexate—testicular cancer	0.0129	0.0177	CcSEcCtD
Tazarotene—RARA—female gonad—testicular cancer	0.0126	0.0892	CbGeAlD
Tazarotene—Leukoderma—Epirubicin—testicular cancer	0.0121	0.0166	CcSEcCtD
Tazarotene—Inflammation—Ifosfamide—testicular cancer	0.0119	0.0164	CcSEcCtD
Tazarotene—RARG—testis—testicular cancer	0.0119	0.0842	CbGeAlD
Tazarotene—RARA—testis—testicular cancer	0.0112	0.0791	CbGeAlD
Tazarotene—Leukoderma—Doxorubicin—testicular cancer	0.0112	0.0153	CcSEcCtD
Tazarotene—Skin exfoliation—Ifosfamide—testicular cancer	0.0111	0.0152	CcSEcCtD
Tazarotene—RARB—lymph node—testicular cancer	0.0106	0.0748	CbGeAlD
Tazarotene—Pain—Carboplatin—testicular cancer	0.0104	0.0143	CcSEcCtD
Tazarotene—Skin discolouration—Etoposide—testicular cancer	0.0101	0.0139	CcSEcCtD
Tazarotene—Skin exfoliation—Cisplatin—testicular cancer	0.00953	0.0131	CcSEcCtD
Tazarotene—Swelling—Ifosfamide—testicular cancer	0.00953	0.0131	CcSEcCtD
Tazarotene—Inflammation—Etoposide—testicular cancer	0.00943	0.013	CcSEcCtD
Tazarotene—Skin hyperpigmentation—Methotrexate—testicular cancer	0.00921	0.0127	CcSEcCtD
Tazarotene—Skin exfoliation—Etoposide—testicular cancer	0.00873	0.012	CcSEcCtD
Tazarotene—RARG—lymph node—testicular cancer	0.00863	0.061	CbGeAlD
Tazarotene—Skin hyperpigmentation—Epirubicin—testicular cancer	0.00862	0.0118	CcSEcCtD
Tazarotene—RARA—lymph node—testicular cancer	0.00811	0.0574	CbGeAlD
Tazarotene—Haemoglobin—Vinblastine—testicular cancer	0.0081	0.0111	CcSEcCtD
Tazarotene—Haemorrhage—Vinblastine—testicular cancer	0.00806	0.0111	CcSEcCtD
Tazarotene—Skin hyperpigmentation—Doxorubicin—testicular cancer	0.00798	0.011	CcSEcCtD
Tazarotene—Burning sensation—Methotrexate—testicular cancer	0.00789	0.0108	CcSEcCtD
Tazarotene—Swelling—Etoposide—testicular cancer	0.00753	0.0103	CcSEcCtD
Tazarotene—Burning sensation—Epirubicin—testicular cancer	0.00738	0.0101	CcSEcCtD
Tazarotene—Blister—Epirubicin—testicular cancer	0.00711	0.00977	CcSEcCtD
Tazarotene—Haemoglobin—Bleomycin—testicular cancer	0.00684	0.0094	CcSEcCtD
Tazarotene—Burning sensation—Doxorubicin—testicular cancer	0.00683	0.00938	CcSEcCtD
Tazarotene—Haemorrhage—Bleomycin—testicular cancer	0.00681	0.00935	CcSEcCtD
Tazarotene—Blister—Doxorubicin—testicular cancer	0.00658	0.00904	CcSEcCtD
Tazarotene—Stinging—Epirubicin—testicular cancer	0.00633	0.0087	CcSEcCtD
Tazarotene—Skin discolouration—Methotrexate—testicular cancer	0.00607	0.00833	CcSEcCtD
Tazarotene—Erythema—Bleomycin—testicular cancer	0.00592	0.00814	CcSEcCtD
Tazarotene—Discomfort—Vinblastine—testicular cancer	0.0059	0.00811	CcSEcCtD
Tazarotene—Stinging—Doxorubicin—testicular cancer	0.00586	0.00805	CcSEcCtD
Tazarotene—Haemoglobin—Ifosfamide—testicular cancer	0.00585	0.00803	CcSEcCtD
Tazarotene—Haemorrhage—Ifosfamide—testicular cancer	0.00582	0.00799	CcSEcCtD
Tazarotene—Skin discolouration—Epirubicin—testicular cancer	0.00568	0.0078	CcSEcCtD
Tazarotene—Inflammation—Methotrexate—testicular cancer	0.00565	0.00776	CcSEcCtD
Tazarotene—Erythema—Dactinomycin—testicular cancer	0.00553	0.00759	CcSEcCtD
Tazarotene—Pain—Chlorambucil—testicular cancer	0.00534	0.00734	CcSEcCtD
Tazarotene—Inflammation—Epirubicin—testicular cancer	0.00529	0.00726	CcSEcCtD
Tazarotene—Skin discolouration—Doxorubicin—testicular cancer	0.00525	0.00722	CcSEcCtD
Tazarotene—Skin exfoliation—Methotrexate—testicular cancer	0.00523	0.00719	CcSEcCtD
Tazarotene—Dermatitis contact—Epirubicin—testicular cancer	0.00507	0.00696	CcSEcCtD
Tazarotene—Erythema—Ifosfamide—testicular cancer	0.00506	0.00696	CcSEcCtD
Tazarotene—Discomfort—Bleomycin—testicular cancer	0.00498	0.00685	CcSEcCtD
Tazarotene—Pain—Vinblastine—testicular cancer	0.0049	0.00673	CcSEcCtD
Tazarotene—Skin exfoliation—Epirubicin—testicular cancer	0.0049	0.00673	CcSEcCtD
Tazarotene—Inflammation—Doxorubicin—testicular cancer	0.00489	0.00672	CcSEcCtD
Tazarotene—Oedema—Bleomycin—testicular cancer	0.00484	0.00664	CcSEcCtD
Tazarotene—Dermatitis contact—Doxorubicin—testicular cancer	0.00469	0.00644	CcSEcCtD
Tazarotene—Discomfort—Dactinomycin—testicular cancer	0.00465	0.00638	CcSEcCtD
Tazarotene—Skin exfoliation—Doxorubicin—testicular cancer	0.00453	0.00622	CcSEcCtD
Tazarotene—Oedema—Dactinomycin—testicular cancer	0.00451	0.0062	CcSEcCtD
Tazarotene—CYP2C8—testis—testicular cancer	0.00443	0.0314	CbGeAlD
Tazarotene—Pruritus—Chlorambucil—testicular cancer	0.00442	0.00607	CcSEcCtD
Tazarotene—Erythema—Cisplatin—testicular cancer	0.00437	0.006	CcSEcCtD
Tazarotene—Discomfort—Ifosfamide—testicular cancer	0.00426	0.00585	CcSEcCtD
Tazarotene—Eczema—Epirubicin—testicular cancer	0.00414	0.00569	CcSEcCtD
Tazarotene—Pain—Bleomycin—testicular cancer	0.00414	0.00568	CcSEcCtD
Tazarotene—Oedema—Ifosfamide—testicular cancer	0.00413	0.00568	CcSEcCtD
Tazarotene—Dermatitis bullous—Epirubicin—testicular cancer	0.00389	0.00535	CcSEcCtD
Tazarotene—Pain—Dactinomycin—testicular cancer	0.00386	0.0053	CcSEcCtD
Tazarotene—Eczema—Doxorubicin—testicular cancer	0.00383	0.00527	CcSEcCtD
Tazarotene—Discomfort—Cisplatin—testicular cancer	0.00367	0.00504	CcSEcCtD
Tazarotene—Dermatitis bullous—Doxorubicin—testicular cancer	0.0036	0.00495	CcSEcCtD
Tazarotene—Oedema—Cisplatin—testicular cancer	0.00356	0.00489	CcSEcCtD
Tazarotene—Pain—Ifosfamide—testicular cancer	0.00353	0.00485	CcSEcCtD
Tazarotene—Pruritus—Bleomycin—testicular cancer	0.00342	0.0047	CcSEcCtD
Tazarotene—Dry skin—Epirubicin—testicular cancer	0.00341	0.00469	CcSEcCtD
Tazarotene—Discomfort—Etoposide—testicular cancer	0.00336	0.00462	CcSEcCtD
Tazarotene—Dry skin—Doxorubicin—testicular cancer	0.00316	0.00434	CcSEcCtD
Tazarotene—Photosensitivity reaction—Methotrexate—testicular cancer	0.00314	0.00431	CcSEcCtD
Tazarotene—Rash—Bleomycin—testicular cancer	0.00305	0.00419	CcSEcCtD
Tazarotene—Pain—Cisplatin—testicular cancer	0.00305	0.00419	CcSEcCtD
Tazarotene—Dermatitis—Bleomycin—testicular cancer	0.00305	0.00418	CcSEcCtD
Tazarotene—Photosensitivity reaction—Epirubicin—testicular cancer	0.00294	0.00403	CcSEcCtD
Tazarotene—Pruritus—Ifosfamide—testicular cancer	0.00292	0.00402	CcSEcCtD
Tazarotene—Rash—Dactinomycin—testicular cancer	0.00284	0.00391	CcSEcCtD
Tazarotene—Pain—Etoposide—testicular cancer	0.00279	0.00383	CcSEcCtD
Tazarotene—Haemoglobin—Methotrexate—testicular cancer	0.00277	0.0038	CcSEcCtD
Tazarotene—Haemorrhage—Methotrexate—testicular cancer	0.00275	0.00378	CcSEcCtD
Tazarotene—Photosensitivity reaction—Doxorubicin—testicular cancer	0.00272	0.00373	CcSEcCtD
Tazarotene—Rash—Ifosfamide—testicular cancer	0.00261	0.00358	CcSEcCtD
Tazarotene—Dermatitis—Ifosfamide—testicular cancer	0.0026	0.00358	CcSEcCtD
Tazarotene—Haemoglobin—Epirubicin—testicular cancer	0.00259	0.00356	CcSEcCtD
Tazarotene—Haemorrhage—Epirubicin—testicular cancer	0.00258	0.00354	CcSEcCtD
Tazarotene—Oedema peripheral—Epirubicin—testicular cancer	0.00254	0.00348	CcSEcCtD
Tazarotene—Erythema—Methotrexate—testicular cancer	0.0024	0.00329	CcSEcCtD
Tazarotene—Haemoglobin—Doxorubicin—testicular cancer	0.00239	0.00329	CcSEcCtD
Tazarotene—Haemorrhage—Doxorubicin—testicular cancer	0.00238	0.00327	CcSEcCtD
Tazarotene—Oedema peripheral—Doxorubicin—testicular cancer	0.00235	0.00322	CcSEcCtD
Tazarotene—Pruritus—Etoposide—testicular cancer	0.00231	0.00317	CcSEcCtD
Tazarotene—Rash—Cisplatin—testicular cancer	0.00225	0.00309	CcSEcCtD
Tazarotene—Dermatitis—Cisplatin—testicular cancer	0.00224	0.00308	CcSEcCtD
Tazarotene—Erythema—Epirubicin—testicular cancer	0.00224	0.00308	CcSEcCtD
Tazarotene—Erythema—Doxorubicin—testicular cancer	0.00207	0.00285	CcSEcCtD
Tazarotene—Rash—Etoposide—testicular cancer	0.00206	0.00283	CcSEcCtD
Tazarotene—Dermatitis—Etoposide—testicular cancer	0.00206	0.00282	CcSEcCtD
Tazarotene—Discomfort—Methotrexate—testicular cancer	0.00202	0.00277	CcSEcCtD
Tazarotene—Discomfort—Epirubicin—testicular cancer	0.00189	0.00259	CcSEcCtD
Tazarotene—Oedema—Epirubicin—testicular cancer	0.00183	0.00251	CcSEcCtD
Tazarotene—Discomfort—Doxorubicin—testicular cancer	0.00174	0.0024	CcSEcCtD
Tazarotene—Oedema—Doxorubicin—testicular cancer	0.00169	0.00233	CcSEcCtD
Tazarotene—Pain—Methotrexate—testicular cancer	0.00167	0.0023	CcSEcCtD
Tazarotene—Pain—Epirubicin—testicular cancer	0.00156	0.00215	CcSEcCtD
Tazarotene—Pain—Doxorubicin—testicular cancer	0.00145	0.00199	CcSEcCtD
Tazarotene—Pruritus—Methotrexate—testicular cancer	0.00138	0.0019	CcSEcCtD
Tazarotene—Pruritus—Epirubicin—testicular cancer	0.00129	0.00178	CcSEcCtD
Tazarotene—Rash—Methotrexate—testicular cancer	0.00123	0.00169	CcSEcCtD
Tazarotene—Dermatitis—Methotrexate—testicular cancer	0.00123	0.00169	CcSEcCtD
Tazarotene—Pruritus—Doxorubicin—testicular cancer	0.0012	0.00165	CcSEcCtD
Tazarotene—Rash—Epirubicin—testicular cancer	0.00115	0.00158	CcSEcCtD
Tazarotene—Dermatitis—Epirubicin—testicular cancer	0.00115	0.00158	CcSEcCtD
Tazarotene—Rash—Doxorubicin—testicular cancer	0.00107	0.00147	CcSEcCtD
Tazarotene—Dermatitis—Doxorubicin—testicular cancer	0.00107	0.00146	CcSEcCtD
